BioCentury
ARTICLE | Company News

Shire earnings check Takeda's boxes

August 3, 2018 5:32 PM UTC

With its acquisition by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) due to close next half, Shire plc (LSE:SHP; NASDAQ:SHPG) reported 5% growth in 2Q18 revenue over 2Q17, outpacing the Japanese pharma's 0.4% growth over the same period.

Shire's EBITDA margins remained strong, coming in at 42% in 2Q18 and 43% in 2Q17. Takeda expects Shire’s higher profit margins to drive earnings accretion that will help maintain its credit rating (see "Takeda Hits the Gas")...